Published • loading... • Updated
Supernus Closes 2025 With Record Revenue, Then Agrees to a Merger With Indivior - Insights Success
Summary by InsightsSuccess
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Supernus Closes 2025 With Record Revenue, Then Agrees to a Merger With Indivior - Insights Success
Supernus Pharmaceuticals closed out 2025 with record revenue of $719 million. Five months later, on Aug. 3, it agreed to fold into a larger company altogether, striking an all-stock merger with Indivior Pharmaceuticals. Four Growth Products Take Over Supernus reported full-year 2025 revenue of $719 million, up 9 percent from 2024, with fourth-quarter revenue of $211.6 million, up 21 percent. Four products the company calls its growth drivers, Qe…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
